

compounds or a materially different product, the result would not be the same. The compound of group I provides novel activity at the immune regulatory protein B7-1, which is crucial to the method of treating a disorder related to or affected by the B7-1 protein that comprises group II. The searches required for each of the above-identified groups overlap to the extent that such searches would not present an undue burden to Examiner. For the foregoing reasons, Applicants respectfully request that Examiner reconsider and withdraw the restriction set forth.


ELECTION

Notwithstanding the above, and solely in compliance with the provisions of 37 CFR §1.143, Applicants hereby provisionally elect group I, claims 1-9 and 15-20, for prosecution herein. Applicants gratefully acknowledge Examiner's indication that rejoinder is possible once a claim has been found allowable.

The remaining claims have not been cancelled in order to provide the Examiner the opportunity to reconsider and withdraw the restriction requirement. Applicants reserve the right to file a divisional application on the non-elected subject matter.

Favorable treatment of the application is earnestly solicited.

Respectfully submitted,


Barbara L. Lences
Agent for Applicants
Reg. No. 41,148

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (732) 274-4678